目的 探討采用奧替溴銨聯合柳氮磺吡啶治療潰瘍性結腸炎的有效性與安全性。方法 選取2016年3月-2017年3月赤峰學院附屬醫(yī)院收治的潰瘍性結腸炎患者121例，隨機分成對照組（60例）和治療組（61例）。對照組患者口服柳氮磺吡啶腸溶片，6片/次，3次/d。治療組在對照組的基礎上口服奧替溴銨片，2片/次，3次/d。兩組患者均連續(xù)治療8周。觀察兩組患者臨床療效，比較治療前后兩組患者臨床癥狀恢復時間、臨床活動指數、炎癥因子和腸黏膜TLR-4水平。結果 治療后，對照組和治療組的臨床有效率分別為81.67%和95.08%，兩組比較差異具有統(tǒng)計學意義（P<0.05）。治療后，兩組患者臨床活動指數評分均顯著降低（P<0.05），且治療后治療組患者臨床活動指數評分顯著低于對照組（P<0.05），治療組患者血便消失時間、腹瀉癥狀恢復時間均顯著短于對照組患者（P<0.05）。治療后，兩組患者的IL-6、TNF-α血清水平和腸黏膜TLR-4組織水平均顯著降低，同組比較差異具有統(tǒng)計學意義（P<0.05）；且治療組IL-6、TNF-α和TLR-4水平明顯低于對照組，兩組比較差異具有統(tǒng)計學意義（P<0.05）。結論 奧替溴銨聯合柳氮磺吡啶治療潰瘍性結腸炎療效好、不良反應少，具有一定的臨床推廣應用價值。

Objective To investigate the efficacy and safety of otibromide combined with sulfasalazine in treatment of ulcerative colitis. Methods Patients (121 cases) with ulcerative colitis in Affiliated Hospital of Chifeng University from March 2016 to March 2017 were randomly divided into control (60 cases) and treatment (61 cases) groups. Patients in the control group were po administered with Sulfasalazine Enteric-coated Tablets, 6 tablets/time, three times daily. Patients in the treatment group were po administered with Otilonium Bromide Tablets on the basis of the control group, 2 tablets/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacy was evaluated, and the clinical symptoms recovery time, clinical activity index, the inflammatory factors and TLR-4 levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups was 81.67% and 95.08%, respectively, and there were differences between two groups (P<0.05). After treatment, the clinical activity index score in two groups was significantly decreased (P<0.05), and the score in the treatment group after treatment was significantly lower than that in the control group (P<0.05). After treatment, the disappearance time bloody stool and diarrhea in the treatment group after treatment was earlier than that in the control group (P<0.05). After treatment, the IL-6, TNF-α and TLR-4 levels in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the IL-6, TNF-α and TLR-4 levels in the treatment group after treatment were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion otibromide combined with sulfasalazine in treatment of ulcerative colitis has good curative effect and high safety, which has a certain clinical application value.